

Correction to *Lancet Gastroenterol Hepatol* 2024; 9: 34–44

been made to the online version as of June 10, 2024, and the printed version is correct.

Yuan X-L, Liu W, Lin Y-X, et al. *Effect of an artificial intelligence-assisted system on endoscopic diagnosis of superficial oesophageal squamous cell carcinoma and precancerous lesions: a multicentre, tandem, double-blind, randomised controlled trial.* *Lancet Gastroenterol Hepatol* 2024; 9: 34–44—In this Article, a new second sentence has been added to the Methods, Study design and participants section, which reads: “A further three hospitals had been invited to participate, but due to technical issues did not enrol patients or participate further in the trial.” The Declaration of interests statement for BH should read: “BH has received funding support from the National Natural Science Foundation of China (grant number 82170675) and the 1-3-5 project for disciplines of excellence, West China Hospital, Sichuan University (grant number ZYJC21011). BH has received honoraria for lectures from Olympus Corporation. BH is chief scientist at Xiamen Innovision Medical Technology; this role is unpaid and without any associated consulting fees.” These corrections have been made to the online version as of June 10, 2024.

Correction to *Lancet Gastroenterol Hepatol* 2024; 9: 620–31

Miethke AG, Moukarzel A, Porta G, et al. *Maralixibat in progressive familial intrahepatic cholestasis (MARCH-PFIC): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.* *Lancet Gastroenterol Hepatol* 2024; 9: 620–31—In figure 3 of this Article, the lines in the key the All-PFIC and BSEP cohorts in the placebo group were inverted. This correction has